title: Enzalutamide: a new prostate cancer targeted therapy against the androgen receptor.
abstract: Enzalutamide (MDV3100), an androgen receptor-signalling inhibitor, represents the most recent compound added to the therapeutic armamentarium for the treatment of metastatic castration-resistant prostate cancer (mCRPC) who progressed to docetaxel. The anti-tumour activity and safety of enzalutamide has been demonstrated in a phase III clinical trial, showing a benefit in overall survival, which was the primary endpoint. There are no head-to-head studies comparing the different treatment options in this subset of patients. In this article, most relevant data published in the literature have been reviewed, with special attention to the therapeutic alternatives currently available for postdocexatel mCRPC patients, emphasising the mechanisms of action of the different drugs, efficacy and quality of life-related aspects.
authors: Oncología Médica, Complexo Hospitalario Universitario de Vigo, C/Pizarro 22, 36204 Vigo, Spain. Electronic address: martin.lazaro.quintela@sergas.es.
authors: Martín Lázaro
authors: ML
authors: Quintela
authors: Servicio de Oncología Médica, Complexo Hospitalario Universitario de Pontevedra, Spain. Electronic address: luis.leon.mateos@sergas.es.
authors: Luis León
authors: LL
authors: Mateos
authors: Servicio de Oncología Médica, Hospital Universitario Lucus Augusti, C/Doutor Ulises Romero, s/n, 27003 Lugo, Spain. Electronic address: sergio.vazquez.estevez@sergas.es.
authors: Sergio Vázquez
authors: SV
authors: Estévez
authors: Servicio Oncologia Medica, Complejo Hospitalario Universitario Ourense, C/Ramón Puga 54.32005, Spain. Electronic address: ovidiofernandezcalvo@yahoo.es.
authors: Ovidio Fernández
authors: OF
authors: Calvo
authors: Oncología Médica, Complejo Hospitalario Universitario de Santiago de Compostela, c/Choupana s/n, 15706 Santiago de Compostela, A Coruña, Spain. Electronic address: urbanoanido@gmail.com.
authors: Urbano Anido
authors: UA
authors: Herranz
authors: Oncología Médica, C.H.U.Ferrol, Ferrol, A Coruña, Spain. Electronic address: Francisco.Javier.Afonso.Afonso@sergas.es.
authors: Francisco Javier Afonso
authors: FJ
authors: Afonso
authors: Servicio de Oncología Médica, Hospital Povisa, C/Salamanca 5, 36211 Vigo, Spain. Electronic address: lsantome@povisa.es.
authors: Lucía
authors: L
authors: Santomé
authors: Medical Oncology Service, CHUA Coruña, Spain. Electronic address: luis.anton.aparicio@sergas.es.
authors: Luis Antón
authors: LA
authors: Aparicio
mesh_terms: D059002:Androgen Receptor Antagonists / Q000494:pharmacology* / Q000627:therapeutic use*; D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D001549:Benzamides; D006801:Humans; D008297:Male; D058990:Molecular Targeted Therapy; D009570:Nitriles; D010669:Phenylthiohydantoin / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D064129:Prostatic Neoplasms, Castration-Resistant / Q000188:drug therapy* / Q000378:metabolism
chemical_list: D059002:Androgen Receptor Antagonists; D000970:Antineoplastic Agents; D001549:Benzamides; D009570:Nitriles; D010669:Phenylthiohydantoin; C540278:enzalutamide
keywords: Abiraterone; Cabazitaxel; Docetaxel; Enzalutamide; Metastatic castration-resistant prostate cancer